← Immatics N.V. (IMTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Immatics N.V. (IMTX)
Biological Products, (No Diagnostic Substances) · market cap $1.2B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-16 (est.)
Earnings
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Immatics N.V. (IMTX) is a clinical-stage biological products company with 645 employees and a market cap of approximately $1.34B at ~$9.59/share. Its lead asset, IMA203, is in Phase 3 development for cutaneous malignant melanoma, with a secondary program (IMA203 Product) in Phase 2 for refractory cancer. The next scheduled catalyst is an earnings release on August 12, 2026.
The catalyst path
- 2026-11-16 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IMA 950 | Phase 2 | CNS Tumor, Adult |
| IMA203 | Phase 3 | Melanoma, Cutaneous Malignant |
| IMA203 Product | Phase 2 | Refractory Cancer |
| IMA970A plus CV8102 and Cyclophosphamide | Phase 2 | Hepatocellular Carcinoma |
| GM-CSF | Phase 3 | Metastatic Renal Cell Carcinoma |
Price & technical context
3-month
-15.2%
6-month
-15.7%
12-month
-0.9%
52-wk range
$8.33–$11.87
vs 50-day MA
-6.9%
vs 200-day MA
-14.4%
Realized vol
58.7%
Max drawdown
-72.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.